Challenging Conventional Care

If it looks really challenging and it's for a good cause, you can clear Julie Papanek's calendar. Julie biked 4000 miles across the country to raise money for Habitat for Humanity, and has competed in triathlons to benefit the Leukemia and Lymphoma Society. It's no secret that Julie takes the same approach when investing. Better startups just aren't enough... she wants better patient outcomes.

Julie brings operational experience from biotechnology and healthIT and currently sits on the board of Protagonist Therapeutics (PTGX). Julie has also worked closely with and observed on the boards of CytomX, Labrys Biologics, Dermira, ALDEA Pharmaceuticals, Chrono Therapeutics, and Glooko. Julie also serves on the board of the Biden Cancer Initiative. The San Francisco Business Times named Julie to the 40 Under 40 Class of 2017 in recognition of her contributions to Bay Area business.

Prior to Canaan, Julie worked at Genentech in a variety of positions spanning marketing, development, and business development. This included creating commercial brand plans, forecasting, and recommending modifications to Phase III trials designs for marketed and pipeline oncology products. She advises a number of digital health and BioPharma companies on business development and go to market strategy. Personally, Julie has a particular passion for consumer access and affordability to care.

Julie holds an MBA from Stanford's Graduate School of Business, where she was the teaching assistant for the Biodesign Innovation course and an officer of the Healthcare Club. Previously, she earned an MPhil from Cambridge University in BioScience Enterprise and a B.S. from Yale University in Molecular Biophysics and Biochemistry.

Contact Details

+1 650 854 8092
Silicon Valley

"From caring comes courage"

- Lao Tzu

Current Deals

Past Deals

My Favorite Things

High adrenaline sports. Observers may yell "yard sale!" when I ski, and I may spend more time under the water than above it when I kiteboard, but I keep coming back for more.